89Zr-DFO-daratumumab

N/A

Report date: 2025/09/09 15:00:44

Base Information

Drug Name89Zr-DFO-daratumumab

Drug Alias Name[(89)Zr]Zr-DFO-daratumumab89Zr-daratumumab-DFO

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-CD38

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A